FH and hereditary leiomyomatosis and renal cell cancer: Individuals with theclinical diagnosis of HLRCC, individuals with heterozygous mutations in FH without clinical manifestations, and at-riskfamily members who have not undergone molecular genetic testing should have the following regularsurveillance by physicians familiar with the clinical manifestations of HLRCC.